Therapeutics News and Research

RSS

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer’s disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.

16 Dec 2009

Cellular Dynamics International launches iCell Cardiomyocytes

Cellular Dynamics International (CDI) today announced the commercial launch of iCell(TM) Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Drug monitoring may provide alternative treatments for patients with severe H1N1

An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

UCLA researchers find link between brain cancer and fatty acid synthesis

Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

16 Dec 2009

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company’s placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).

15 Dec 2009

Patent for novel method of cutting tissue materials for use in implantable devices issued

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced that the United States Patent and Trademark Office has issued patent number 7,594,974 regarding a novel method of cutting tissue materials for use in implantable devices.

15 Dec 2009

Bend Research makes available Type V DMF for HPMCAS concerning FDA regulatory filings

Bend Research Inc. announced today that its clients may now reference a key safety file for HPMCAS, an excipient used in technologies developed by the firm to enhance the oral bioavailability of clients' low-solubility drugs.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.

15 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Preclinical graft study supports Cytori’s proposed mechanism of action

Cytori Therapeutics reported results from a preclinical cell-enriched fat grafting study supporting the safety and efficacy of Cytori’s method for enriching fat grafts with adipose-derived regenerative cells (ADRCs).

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Therapeutics News and Research

Modulating PN aggregase pathway may offer hope for Alzheimer’s disease

Cellular Dynamics International launches iCell Cardiomyocytes

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Drug monitoring may provide alternative treatments for patients with severe H1N1

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

UCLA researchers find link between brain cancer and fatty acid synthesis

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Patent for novel method of cutting tissue materials for use in implantable devices issued

Bend Research makes available Type V DMF for HPMCAS concerning FDA regulatory filings

Molecular Partners closes its CHF 46 million Series B equity investment round

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Preclinical graft study supports Cytori’s proposed mechanism of action

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News